Okuda-Hiwatashi, S.; Amagai, R.; Fujimura, T.; Kambayashi, Y.; Watanabe-Takahashi, M.; Yamazaki, E.; Tamabuchi, E.; Itabashi, C.; Hashimoto, A.; Asano, Y.
The Evaluation of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in Different Therapy Lines for Metastatic Melanoma: A Retrospective Study. J. Clin. Med. 2024, 13, 5560.
https://doi.org/10.3390/jcm13185560
AMA Style
Okuda-Hiwatashi S, Amagai R, Fujimura T, Kambayashi Y, Watanabe-Takahashi M, Yamazaki E, Tamabuchi E, Itabashi C, Hashimoto A, Asano Y.
The Evaluation of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in Different Therapy Lines for Metastatic Melanoma: A Retrospective Study. Journal of Clinical Medicine. 2024; 13(18):5560.
https://doi.org/10.3390/jcm13185560
Chicago/Turabian Style
Okuda-Hiwatashi, Saki, Ryo Amagai, Taku Fujimura, Yumi Kambayashi, Manami Watanabe-Takahashi, Emi Yamazaki, Erika Tamabuchi, Chisato Itabashi, Akira Hashimoto, and Yoshihide Asano.
2024. "The Evaluation of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in Different Therapy Lines for Metastatic Melanoma: A Retrospective Study" Journal of Clinical Medicine 13, no. 18: 5560.
https://doi.org/10.3390/jcm13185560
APA Style
Okuda-Hiwatashi, S., Amagai, R., Fujimura, T., Kambayashi, Y., Watanabe-Takahashi, M., Yamazaki, E., Tamabuchi, E., Itabashi, C., Hashimoto, A., & Asano, Y.
(2024). The Evaluation of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in Different Therapy Lines for Metastatic Melanoma: A Retrospective Study. Journal of Clinical Medicine, 13(18), 5560.
https://doi.org/10.3390/jcm13185560
